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Abstract Stem cells (SCs) are a promising approach to re-
generative medicine, with the potential to treat numerous or-
thopedic disorders, including osteo-degenerative diseases.
The development of human-induced pluripotent stem cells
(hiPSCs) has increased the potential of SCs for new treat-
ments. However, current methods of differentiating hiPSCs
into chondrocyte-like cells are suboptimal and better methods
are needed. The aim of the present study was to assess four
different chondrogenic differentiation protocols to identify the
most efficient method of generating hiPSC-derived
chondrocytes. For this study, hiPSCs were obtained from pri-
mary human dermal fibroblasts (PHDFs) and differentiated
into chondrocyte-like cells using four different protocols: 1)
monolayer culture with defined growth factors (GF); 2) em-
bryoid bodies (EBs) in a chondrogenic medium with TGF-β3
cells; 3) EBs in chondrogenic medium conditioned with hu-
man chondrocytes (HC-402-05a cell line) and 4) EBs in
chondrogenic medium conditioned with human chondrocytes
and supplemented with TGF-β3. The cells obtained through
these four protocols were evaluated and compared at the
mRNA and protein levels. Although chondrogenic differenti-
ation of hiPSCs was successfully achieved with all of these
protocols, the two fastest and most cost-effective methods
were the monolayer culture with GFs and the medium condi-
tioned with human chondrocytes. Both of these methods are
superior to other available techniques. The main advantage of
the conditioned medium is that the technique is relatively sim-
ple and inexpensive while the directed method (i.e., monolay-
er culture with GFs) is faster than any protocol described to
date because it is does not require additional steps such as EB
formation.
Keywords Human induced pluripotent stem cells . Cell
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Introduction
Human articular cartilage (AC) has a poor capacity for self-
regeneration, which is why joint disease—typically character-
ized by cartilage degradation—is a serious condition often
only amenable to surgical interventions. Stem cells (SC) are
a highly promising cell replacement therapy to treat cartilage
degradation in common articular diseases such as osteoarthri-
tis [1–3]. Cell-based cartilage tissue engineering for cartilage
regeneration [4] is considered a true breakthrough in the field
of SC research, as shown in the research carried out by
Takahashi and Yamanaka, who obtained pluripotent cells from
human fibroblasts [5, 6]. Defined transcription factors can be
used to transform terminally-differentiated cells into human
induced pluripotent stem cells (hiPSCs), giving rise to SCs
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that share a wide range of characteristics with human embry-
onic SCs (hESCs) [7].
Numerous techniques for chondrogenic differentiation of
hiPSCs are available, including micromass culture, directed
differentiation, pellet culture, and embryoid body (EB) forma-
tion (the most common method) [8]. However, all of these
techniques have shortcomings, particularly with regards to
their efficiency in differentiating hiPSC cells into
chondrocyte-like cells [9, 10]. Thus, it is important to empha-
size that, in an attempt to develop a faster and more cost-
effective method, our group developed a novel directed differ-
entiation technique involving the use of a monolayer culture
with added growth factors (GFs). The advantage of this ap-
proach is that no additional steps (e.g., EB formation) are
required and, moreover, only relatively small amounts of
GFs are needed.
The main aim of this study was to evaluate and compare
four different hiPSC chondrogenic differentiation protocols to
identify the most efficient and least expensive method(s) of
generating chondrocyte-like cells. We evaluated the following
methods: 1) monolayer culture with the addition of defined
GFs (DIRECT protocol), 2) EBs differentiated in
chondrogenic medium with TGF-β3 cells (TGF-β3
protocol) [modified 11], 3) EBs differentiated in chondrogenic
medium conditioned with human chondrocytes (HC-402-05a
cell line) (COND protocol), and 4) EBs differentiated in
chondrogenic medium conditioned with human chondrocytes
and supplemented with TGF-β3 (TGF-β3+ COND protocol).
Our findings indicate that hiPSCs can be successfully dif-
ferentiated into chondrogenic lineages using all four of these
protocols. The cells obtained with all of these methods pre-
sented the characteristics of mature chondrocytes. We found
that both the conditioned medium (COND protocol) and the
DIRECT protocol allowed us to obtain chondrocyte-like cells
quickly and inexpensively. Furthermore, the novel directed
differentiation protocol produced chondrocyte-like cells
whose properties were comparable to cells differentiated
through the better-known approach of EB formation in the
presence of TGF-β3. The use of this new method could help
to reduce the time and expense of producing cells for use in
regenerative medicine. This study contributes to a greater un-
derstanding of the role of hiPSCs in regenerativemedicine and
should help to further develop fully functional chondrocytes
derived from SCs.
Materials and Methods
Culturing Human Induced Pluripotent Stem Cells
We seeded the hiPSCs—obtained through a reprogramming
process described previously [12]—on 10-cm Petri dishes in
Matrigel (Becton Dickinson) coated previously with
inactivated murine embryonic fibroblasts (MEFs) as a feeder
layer (1 × 106). After 24 h, the hiPSCs were seeded at 2 × 106
in hiPSC growth medium consisting of the following: DMEM
F12 with L-Glutamine (Merck Millipore, Germany); 20%
KSR (Thermo Fisher Scientific, MA, USA); 1% NEAA
(Merck Millipore, Germany); 0.1 mM β-mercaptoethanol
(Merck Millipore, Germany); and 1% P/S (Merck Millipore,
Germany). Prior to use, the medium was supplemented with
fibroblast growth factor 2 (FGF-2) (10 ng/ml) (Merck
Millipore, Germany). The culture medium was changed daily.
Chondrogenesis in Vitro
We used a standard chondrogenic medium, as follows:
DMEM F12 with L-Glutamine; 10% FBS (Biowest,
France); 50 μM L-proline (Sigma Aldrich, MO, USA);
50 μM ascorbic acid (Sigma Aldrich, MO, USA); 1 mM so-
dium pyruvate (Biowest, France); 1% ITS + Premix (Corning,
NY, USA); 1% P/S and 10−7 M dexamethasone (Sigma
Aldrich, MO USA).
Chondrogenesis via Monolayer Culture (DIRECT
Protocol)
Firstly, hiPSCs were cultured for 1 week in a pro-mesodermal
medium consisting of the following: DMEM F12 with L-
Glutamine, 10% FBS supplemented with FGF-2 (10 ng/ml);
BMP-4 (10 ng/ml) (ImmunoTools, Germany); and PDGF-BB
(10 ng/ml) (PeproTech, UK). Then, the medium was replaced
with a standard chondrogenic medium supplemented with
TGF-β3 (10 ng/ml) (ImmunoTools, Germany) for another
week. After that, themediumwas replacedwith a chondrogenic
medium supplemented with TGF-β3 (10 ng/ml) and IGF-1
(10 ng/ml) (Peprotech, UK) for one final week of enhanced
chondrogenesis in vitro (DIRECT protocol; Fig. 1a)
Embryoid Body Formation
At 80% confluency, hiPSC colonies were passaged and disso-
ciated into clumps with 0.1% collagenase IV solution
(Thermo Fisher Scientific; Massachusetts, USA). The cells
were centrifuged to remove collagenase and transferred into
non-adherent 96-well plates (1000 cells per well) (Brand,
Germany) in EB growth medium (a hiPSC growth medium
without FGF-2). The EBs formed within 24 h and were visible
as free-floating aggregates. The culture medium was changed
every 48 h. On day 7 the EBs were used for chondrogenic
differentiation.
Medium Conditioning
A standard chondrogenic medium was used for conditioning:
DMEM F12 with L-Glutamine; 10% FBS; 50 μM L-proline;
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50 μM ascorbic acid; 1 mM sodium pyruvate; 1% ITS +
Premix; 1% P/S; and 10−7 M dexamethasone. This condition-
ing mediumwas used for the HC-402-05a cell line. After 24 h,
the conditioned mediumwas collected and administered to the
differentiated EBs.
Chondrogenesis Using Embryoid Bodies
The mature EBs were transferred onto 6-well plates (10 EBs
per well) previously coated with 0.1% gelatin (Merck
Millipore, Germany) and allowed to adhere for the next
24 h. After 24 h, the medium was replaced with one of the
following: 1) a chondrogenic medium supplemented with
TGF-β3 (10 ng/ml) (TGF-β3 protocol; Fig. 1b), considered
to be the GF with the most chondrogenic potential; 2) a
chondrogenic medium conditioned on the HC-402-05a cell
line (COND protocol; Fig. 1c or 3) a chondrogenic medium
conditioned on the HC-402-05a cell line supplemented with
TGF-β3 (10 ng/ml) (TGF-β3+ COND protocol; Fig. 1d). The
positive effect of standard chondrogenic medium containing
exogenous TGF-β3 (10 ng/ml) on pluripotent SCs was previ-
ously tested and confirmed in our laboratory [13]. The
chondrogenic medium was changed every 48 h. The total
culturing period was 21 days. In all analyses, a stable cell line
of adult human articular chondrocytes (HC-402-05a) served
as a positive control based on the recommendations of the
European Collection of Authenticated Cell Cultures
(ECACC) for evaluation of the differentiation process in
in vitro model systems (https://www.pheculturecollections.
o rg . uk / p r oduc t s / c e l l l i n e s / p r ima r y c e l l s / d e t a i l .
jsp?refId=06090702&collection=ecacc_nepc).
Reverse Transcriptase-PCR and Real-Time PCR
Total RNA was extracted from cells with Trizol (Sigma
Aldrich, MO, USA). One μg of total RNA per 20 μl reaction
volume was reverse-transcribed using the iScript™ cDNA
Synthesis Kit (Bio-Rad, CA, USA). Real Time-PCR reactions
were performed using the LightCycler® 480 Probes Master
(Roche, Switzerland) and the appropriate probe for each prim-
er. cDNA samples were analyzed for genes of interest and for
the reference gene GAPDH (05-190-541-001, Roche
Diagnostics, Switzerland), selected based on recently pub-
lished data on chondrogenic differentiation of hiPSCs [14].
Fig. 1 HiPSCs were
differentiated through four
different protocols: a monolayer
culture with a set of defined
growth factors (GF) (DIRECT
protocol); b embryoid bodies
(EB) with the exogenous addition
of TGF-β3 (TGF-β3 protocol); c
EBs in a medium conditioned on
the HC-402-05 cell line (COND
protocol); and d EBs in a
conditioned medium
supplemented with TGF-β3
(TGF-β3+ COND protocol). In
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The expression level for each target gene was calculated as -
2ΔΔct. The reaction was performed in triplicate for the gene of
interest. The real-time polymerase chain reaction for individ-
ual genes expression analysis was carried out using
LightCycler 96 with specific primers (S Tab. 1) designed with
Universal Probe Library software (Roche Diagnostics,
Switzerland).
Immunofluorescence Analysis
The cells were transferred into a 0.1% gelatin-coated 48-well
plate for 48 h and then washed with phosphate buffered saline
(PBS) (Sigma Aldrich, MO, USA) and fixed for 20 min in
100%methanol (intercellular antigens) (CHEMPUR, Poland)
or 4% formaldehyde (extracellular antigens) (CHEMPUR,
POLAND) (400 μl of methanol/formaldehyde per well).
Then, the cells were rinsed with PBS containing 1% bovine
serum albumin (BSA) (Sigma Aldrich, MO, USA) and incu-
bated for 30 min in PBS containing 1% BSA and 0.2% Triton
X-100 (Sigma Aldrich, MO, USA). After 30 min, the cells
were washed with PBS containing 1% BSA. The primary
antibodies were diluted in PBS containing 1% BSA and
0.2% Triton X-100 and the cells were incubated overnight at
4 °C with the following primary antibodies (all from Abcam
PLC, U.K.): COMP (1:100) (ab128893) ; type II collagen
(1:100) (ab34712); type IX collagen (1:100) (ab134568);
aggrecan (1:85) (ab3778); SOX6 (1:50) (ab30455); SOX9
(1:50) (ab59252); E- cadherin (ab152102) as well as Nanog
(1:50) (MABD24) and OCT3/4 (1:50) (MABD76) (both from
Merck Millipore, Germany). After conjugation with the pri-
mary antibodies, the cells were rinsed three times with PBS
containing 1% BSA. The following secondary antibodies
were diluted with 1% BSA in PBS and incubated in the dark
for 1 h at 37 °C: mouse monoclonal anti-IgG (715-545-150),
mouse monoclonal anti-IgM (715-545-140), and rabbit poly-
clonal ant ibody (1:500) (711-546-152) (Jackson
ImmunoResearch, PA, USA). After the cells were washed
three times with 1% BSA in PBS, they were stained for
5 min with diamidino-2-phenylindole dye (DAPI) (Sigma
Aldrich, MO, USA) solution in water (1:10000) and then
washed with PBS before undergoing microscope analysis.
Signal intensity was evaluated using the ImageJ bioinformat-
ics programme (v. 1.49j; Wayne Rasband, NIH, USA).
Flow Cytometry Analysis
Cells were stained for TRA-1-60, TRA-1-81, CD44, and
CD151 with the anti- human TRA-1-60 (14-8863-82), anti-
human TRA-1-81 (14-8883-82), anti-human/mouse CD44
(14-0441-86), and anti-human CD151 (16-1519-85) antibod-
ies, respectively, according to the manufacturer’s instructions
(all from eBioscience, CA, USA). Briefly, approximately
5 × 105 differentiated and control cells were collected. The
cells were rinsed with PBS and incubated for 30 min at 4 °C
in PBS containing 1% BSA with primary antibodies (0.5 μl
per 100 μl sample). Then, the cells were rinsed with PBS
containing 1% BSA and incubated with the secondary bio-
tinylated antibodies (anti-mouse IgM Biotin, 13-5790-85;
anti-mouse IgG Biotin, 13-4013-85; and anti-rat IgG Biotin,
13-5790-85; all from eBioscience, CA, USA) (0.5 μl per
100 μl sample) in PBS containing 1% BSA for 30 min at
4 °C. Finally, the cells were rinsed and stained with
streptavidin with APC conjugated (17-4317-82) (0.3 μl per
100 μl sample) (eBioscience, CA, USA) for 15 min at room
temperature. The stained cells were rinsed twice, resuspended
in 500 μl in 1x CellFIX (Beckton Dickinson, NJ, USA) and
analyzed with a flow cytometer (BD Accuri® C6) using a
675/25 FL4 filter within 1 h. Fluorescence intensity in arbi-
trary units was plotted in histograms. Data were analyzed
using FlowJo software (FlowJo, LLC; OR, USA).
Statistical Analysis
All experiments were performed at least three times. Results
are reported as means ± standard deviation. Comparisons be-
tween the study groups and controls were performed using the
unpaired Student’s t-test. Statistical tests were performed with
GraphPad Prism (version 5.0a, GraphPad Software, Inc., San
Diego, CA). P values <0.05 were considered significant.
Results
All cells differentiated into chondrogenic lineage via the four
differentiation techniques lost morphology assigned to plurip-
otent SCs and acquired features characteristic for
chondrocytes. In all cases, the differentiated cells were unable
to form colonies, and the cells were long and spindly and
characterized by enhanced production of extracellular matrix
(Fig. 1a, b, c, d). After differentiation, the chondrocyte-like
cells were subjected to further analyses.
Expression of Pluripotency and Chondrogenic Genes
in the Chondrocyte-Like Cells
The pluripotency genes Nanog, octamer-binding transcrip-
tion factor 4 (OCT4), (sex determining region Y)-box 2
(SOX2), and E-cadherin were not expressed in any of the
differentiated cells obtained through the four differentiation
protocols, although these genes were expressed in the original
hiPSCs (Fig. 2a). All hiPSC-derived chondrocytes expressed
the chondrogenic genes type II collagen, (sex determining
region Y)-box 5,6,9 (SOX5,6,9), and NK3 Homeobox 2
(NKX3.2) at variable levels (Fig. 2b). Expression of type II
collagenwas approximately twice as high in the differentiated
cells versus controls (HC-402-05a cell line). Expression of
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SOX Trio genes (SOX5, SOX6 and SOX9) was variable, with
SOX5 expressed in all investigated cells, but at lower levels
than in human articular chondrocytes. However, both SOX6
and SOX9were expressed at higher levels in the chondrocyte-
like cells compared to the positive controls. The mRNA
assigned to NKX3.2 was detected in all differentiated cells,
but most prominently in those obtained via the DIRECT and
TGF-β differentiation methods.
Immunofluorescence Analysis of hiPSC-Derived
Chondrocytes
The results obtained at the mRNA level were confirmed at the
pro te in leve l by immunof luorescence ana lys i s .
Immunofluorescence staining proved the lack of pluripotency
markers Nanog, OCT3/4, and E-cadherin in most differenti-
ated cells. The only cells, which expressed E-cadherin were
those differentiated in the chondrogenic medium with
TGF-β3 (TGF-β3 protocol) (Fig. 3a, c). The differentiated
cells showed the presence of the following chondrogenic
markers: cartilage oligomeric matrix protein (COMP), type
II collagen, type IX collagen, aggrecan, SOX6 and SOX9.
COMP production was high in all the cells obtained through
in vitro chondrogenesis. Type II collagen was present in all
differentiated cells at levels that were similar to those observed
in the control cell line (HC-402-05a cells). Type IX collagen
was detectable in all differentiated cells, with the highest
levels observed in DIRECT cells (at higher levels than seen
in human articular chondrocytes). All the cells obtained by all
four protocols showed very high production of aggrecan,
which was at higher levels than observed in the HC-402-05a
cell line. SOX6 was present in all the cells after chondrogenic
differentiation, with extremely high levels in TGF-β3 cells
and high levels in the DIRECT and TGF-β3+ COND cells.
SOX9 was produced by all differentiated cells, with the
highest production in TGF-β3+ COND cells. We did not ob-
serve any dedifferentiation of hiPSCs: markers present in all
differentiated cells differed significantly from those expressed
by primary human dermal fibroblasts (PHDFs) (Fig. 3b, c).
Flow Cytometry Analysis of Pluripotency
and Chondrogenic Proteins in Differentiated Cells
In all of the differentiated cells (i.e., from all four protocols),
the pluripotencymarkers TRA-1-60 and TRA-1-81 were pres-
ent but at a nearly undetectable levels. Only the positive
control hiPSCs showed a high production of these proteins
(Fig. 4a). The chondrocyte-like cells showed elevated levels
of CD44 and CD151 proteins; however, the most visible shifts
were present in the positive control (HC-402-05a) cell line
(Fig. 4b).
The results obtained at the mRNA level are in compliance
with results representing protein level. It is very difficult to
unambiguously indicate the most efficient protocol of hiPSC
chondrogenic differentiation. We have described four effec-
tive protocols of obtaining chondrocyte-like cells from
hiPSCs because all obtained chondrocyte-like cells lost their
pluripotent nature and first of all, reveal the features charac-
teristic for mature chondrocytes. To selective the most appro-
priate and promising protocol for future clinical applications,
there is a need to consider apart from gene and protein expres-
sion another factors such as the capacity of scale-up, culture
and differentiation duration as well as overall costs. The most
important issues are discussed in the next paragraph.
Discussion
Current methods of differentiating hiPSCs into chondrocyte-
like cells are inefficient and better methods are needed. In the
present study, we evaluated and compared four different pro-
tocols used to differentiate hiPSCs into chondrocyte-like cells.
The main aim was to evaluate and select the most effective
and promising protocol(s) based on gene expression, protein
analyses and time required for cell differentiation for
obtaining chondrocyte-like cells from hiPSCs. We found that
the two most efficient methods were the directed method
(using defined GFs) and the medium conditioned with human
cartilage chondrocytes. To our knowledge, neither of these
protocols has been described previously yet both of these nov-
el chondrogenic stimulators proved to be highly efficient.
Below, we discuss our results in the context of the most recent
data on chondrogenic differentiation of hiPSCs.
Chondrogenic Differentiation in Vitro Using EBs
in the Presence of TGF-β3 is the Most Common Method
of Obtaining hiPSC-Derived Chondrocytes
Most established SC differentiation protocols include EB for-
mation as a structure-containing mesoderm—the most impor-
tant germ layer for induction of chondrogenesis—and further
differentiation in the presence of TGF-β3 (the GF with the
most chondrogenic potential). This approach appears to be the
most effective and well-known [15]. However, an important
drawback of this technique is that the use of EBs requires an
additional step, thus increasing the time required for cell
differentiation.
Villa-Diaz and co-workers [16] reported that hiPSCs cul-
tured in xeno-free conditions can be efficiently differentiated
Fig. 2 The human-induced pluripotent stem cells (hiPSC)-derived
chondrocytes: DIRECT, TGF-β3, COND and TGF-β3 + COND were
analyzed by qPCR. The cells did not express Nanog, OCT4, SOX2, or
E-cadherin a, the genes responsible for maintaining pluripotency. The
differentiated cells expressed chondrogenic genes: type II collagen,
SOX5, SOX6, SOX9 and NKX3.2 b
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intomesenchymal stem cells (MSCs) via EBs and subsequent-
ly into chondrogenic cells in a pellet culture in the presence of
TGF-β3 (10 ng/ml). The high efficiency of this procedure was
confirmed by the Safranin BO^ staining and high expression
of chondrogenic markers [16]. According to Lee and collab-
orators [17], hiPSCs can be efficiently differentiated into
chondrocytes through EBs on fibronectin-coated plates for
14 days using a cocktail of defined GFs. However, note that
this protocol requires a relatively large amount of GFs in high
concentrations (up to 100 ng/ml), making this technique ex-
pensive and, therefore, diminishing its potential clinical appli-
cation [17].
Li et al. [18] found that hiPSCs generated from human
peripheral blood cells can form chondrocyte-like cells. In that
study, the undifferentiated hiPSCs formed EBs, which were
then transferred to gelatin-coated plates. After cellular conflu-
ence, cells were sorted by CD73 and CD105 double positivity
and differentiated into chondrocytes in pellet culture in the
presence of TGF-β1 (10 ng/ml) for 21 days [18]. MSC-like
cells can also be obtained from hiPSCs by monolayer culture
on type I collagen coatings that reflect the structure of physi-
ological collagen, and by further differentiation in the
chondrogenic medium in pellet culture [19]. Craft and co-
workers [20] found that cells with features of streak and
paraxial mesoderm obtained by hiPSC differentiation via
EBs have a strong potential to create chondrocytes in high-
density culture (micromass). In that study, chondrogenic dif-
ferentiation was carried out in a serum-free chondrogenic me-
dium in the presence of TGF-β3, forming stable cartilage
tissue both in vitro and in vivo. Those authors also found that
long-term supplementation with BMP-4 promotes the creation
of undesirable hypertrophic chondrocytes capable of initiating
endochondral ossification in vivo [20]. Ko et al. [21] com-
pared the properties of chondrocytes obtained from hiPSCs
Fig. 3 The presence of chondrogenic markers was demonstrated by
immunofluorescence analysis. The human-induced pluripotent stem cells
(hiPSC)-derived chondrocytes: DIRECT, TGF-β3, COND, TGF-β3+
COND did not reveal the presence of pluripotency markers: Nanog,
OCT4, E-cadherin (a), but they did express desirable chondrogenic
proteins: COMP, type II and IX collagen, aggreccan (AGG), SOX6 and
SOX9 (b). The pluripotency and chondrogenic markers were quantified
to better show the differences between particular differentiation protocols
(c and d)
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with those generated from human bone marrow-derived
MSCs (hBMMSCs). Both cell lines were differentiated via
pellet culture in the presence of TGF-β3, but differentiation
of the hiPSCs was preceded by EB formation. The hiPSC-
derived chondrocytes presented both better glycosaminogly-
can contents and better chondrogenic features. Furthermore,
these cells had significantly reduced undesirable hypertrophic
and osteogenic properties when compared to hBMMSC-
derived chondrocytes [21].
Our results confirm previous reports [15–21] indicating
that the use of EBs increases the efficiency of chondrogenic
differentiation in hiPSCs. Importantly, we demonstrated that
using a conditioned medium could replace (or enhance) the
activity of exogenous TGF-β3. Indeed, hiPSCs differentiated
via EBs in chondrogenic medium with TGF-β3 (TGF-β3
protocol), conditioned chondrogenic medium (COND proto-
col) or conditioned medium supplemented with TGF-β3
(COND + TGF-β3 protocol) (Fig. 1) all possess gene
expression profiles (Fig. 2) and proteins (Figs. 3 and 4) that
are characteristic of fully differentiated chondrocytes (e.g.,
type II collagen, COMP, CD44, SOX Trio).
A Directed Method of hiPSC Chondrogenic
Differentiation Constitutes a Novel, Promising Approach
Nejadnik and colleagues (2015) demonstrated that it is possi-
ble to generate chondrocyte-like cells from hiPSCs via in vitro
differentiation without the need for EB formation. Firstly, they
differentiated hiPSCs intoMSC-like cells for 28 days and then
differentiated these cells into chondrocytes in a high-density
pellet culture in chondrogenic medium with TGF-β3 for an-
other 21 days. Although the results obtained with this protocol
were excellent, it is worth noting that it took 49 days to obtain
the chondrocyte-like cells, thus making this time-consuming
technique a mean candidate for routine differentiation [14].
Fig. 4 The lack of pluripotency markers TRA-1-60 and TRA-1-81 in the differentiated human-induced pluripotent stem cells (hiPSCs) was confirmed
using flow cytometry (a). The chondrogenic markers CD44 and CD151 were observed in these cells
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Based on the previous mentioned work of Nejadnik et al.
[14], our group has developed a novel differentiation protocol
that does not require additional steps (e.g., EB formation) and
only requires relatively small amounts of GFs. The findings
reported in the present study suggest that this novel protocol
could help to improve the process of obtaining chondrocyte-
like cells. The cells obtained from this directed differentiation
protocol presented chondrogenic features (Figs. 2, 3 and 4)
that are comparable to cells differentiated through the well-
known approach involving EB formation in the presence of
TGF-β3. However, our protocol has the advantage of being
more time- and cost-effective than currently available differ-
entiation methods.
Regardless of the technique used to obtain chondrocytes
from hiPSCs, the available evidence [22, 23] suggests that
there may be a risk of tumorigenesis. Although implanted
chondrocytes derived from hiPSCs can successfully regener-
ate cartilage tissue, they may also lead to tumor formation due
to the development of immature teratomas from residual, un-
differentiated hiPSCs; in addition, there is a risk of developing
differentiated tumors, such as chondrosarcomas, originating
from hiPSC-derived chondrocytes with genomic abnormali-
ties [22, 23]. Chondrocytes derived from hiPSCs are therefore
not without risk and more research into the genetic stability of
these chondrocyte-like cells is needed.
Conclusions
In this paper, we have described and compared four different
protocols to obtain chondrocyte-like cells from hiPSCs. Our
findings show that the addition of exogenous mesodermal and
chondrogenic GFs as well as the use of a conditioned medium
ensures that the chondrocyte-like cells present properties that
are equivalent to, or even better than, those obtained from
cultured human articular chondrocytes. Based on our data, it
appears that the directed differentiation protocol presented in
this study may offer an alternative to more expensive and
slower in vitro hiPSC chondrogenic differentiation tech-
niques. The benefit of direct differentiation is that it does not
require additional steps (i.e., EB formation) and takes only
21 days, which is the fastest method reported to date for
obtaining chondrocyte-like cells. Importantly, the use of con-
ditioned medium may enhance the effect of exogenous
TGF-β3 or even obviate the need for this GF, thus offering a
novel and highly cost-effective method of hiPSC
chondrogenic differentiation. Consequently, we believe the
findings presented here may contribute to the development
of more efficient methods of generating hiPSC-derived
chondrocytes. Although we believe these findings represent
an important breakthrough, more data are needed to better
understand key aspects of the nature of chondrogenic hiPSC
differentiation.
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